Guidelines Urge Prompt Aciclovir for Suspected Encephalitis - Medical Independent

Fresh European guidelines on infectious encephalitis in adults advise administering intravenous aciclovir immediately upon suspecting the illness, ideally within a six-hour window.

Developed jointly by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Academy of Neurology (EAN), these recommendations represent the first collaboration between the two bodies and refresh the prior European standards issued back in 2010.

Infectious encephalitis can cause severe neurological injury and long-term disability, yet the evidence supporting many diagnostic and treatment decisions remains limited. The guidance addresses critical gaps in recognizing the condition early, selecting reliable tests, and determining when treatments like antiviral medicines, steroids, or seizure prevention are helpful.

Developed by a taskforce of 19 experts from eight European countries, the recommendations rely on systematic literature searches and the GRADE approach to evaluate 16 clinical questions.

Retain Pathogen-Specific PCR Testing

A central recommendation cautions against replacing pathogen-specific cerebrospinal fluid polymerase chain reaction testing with multiplex PCR panels. While multiplex testing detects multiple pathogens simultaneously, the evidence review found a pooled sensitivity of approximately 76 percent for herpes simplex virus-1, which sits lower than pathogen-specific PCR. Although specificity and sensitivity for other pathogens appeared high, the certainty of the evidence was low, and false-positive results have been documented.

“As a group, we felt that multiplex panels have a role, but they should not replace pathogen-specific CSF PCR in suspected infectious encephalitis. It is worth noting that newer multiplex PCRs are in development which may address these shortcomings,” Dr. Julia Granerod Whitehouse of the EAN-ESCMID Guideline Taskforce said.

When initial results fail to resolve uncertainty, the taskforce advises repeating the lumbar puncture after two to three days if clinical suspicion persists. Microbial antibody testing and screening for neuronal autoantibodies, such as anti-NMDA receptor antibodies in patients who relapse after herpes simplex virus encephalitis, may also be required under specialist advice.

Treating Herpes Simplex Virus Requires Prompt Aciclovir Administration

Prompt intravenous aciclovir remains a primary focus because delays in managing herpes simplex virus can severely worsen outcomes. Clinicians should avoid waiting for diagnostic confirmation if the clinical presentation raises suspicion.

Treatment should only stop if the PCR test is negative and the clinical presentation, CSF findings, and neuroimaging fail to support herpes simplex virus encephalitis. Proven cases warrant a treatment duration of at least 14 days, extended to 21 to 28 days for severe, immunocompromised, or non-improving patients.

On the subject of corticosteroids, the taskforce concluded there is insufficient evidence to recommend either for or against their use in confirmed herpes simplex virus encephalitis. While anti-inflammatory effects might reduce cerebral injury, immunomodulatory properties raise concerns about facilitating viral replication.

The available studies showed neither improved outcomes nor evidence of harm, leaving clinicians free to continue steroids when treating competing conditions like bacterial meningitis or autoimmune encephalitis without risking added harm if herpes simplex virus is later diagnosed.